New phase 2b data presented at the 2026 American Diabetes Association Scientific Sessions suggest that berobenatide, an investigational injectable GLP-1 receptor agonist, may help reduce body weight and A1C in adults with obesity or overweight, including people with type 2 diabetes.
This is early trial news, not a treatment recommendation. Berobenatide is still being studied and is not an approved diabetes or weight-loss medicine. People should not start, stop, or switch any medicine because of conference results.
Key takeaways
- Berobenatide is an investigational GLP-1 receptor agonist being studied in the VESPER trial program.
- In VESPER-2, a 28-week trial in adults with type 2 diabetes and obesity or overweight, ADA Meeting News reported A1C reductions up to 2.2% and body-weight reductions up to 10.2%.
- In VESPER-3, a trial in adults with obesity or overweight plus hypertension and/or dyslipidemia, monthly berobenatide was linked with placebo-adjusted weight loss up to 12.3% at week 28.
- Reported side effects were described as consistent with the GLP-1 medicine class, mainly gastrointestinal symptoms, with no new safety signals in the ADA report.
- The findings need longer follow-up, larger studies, regulatory review, and real-world safety experience before patients can know where this medicine may fit.
Why this matters
Many people with type 2 diabetes also live with obesity or overweight. Medicines in the GLP-1 family can be helpful for some people, but dosing, side effects, access, cost, long-term safety, and individual health risks all matter.
The VESPER results are notable because berobenatide is being studied as a longer-acting option, with potential for monthly dosing in some trial arms. That could be important in the future if later studies confirm benefit and safety. For now, it remains research.
What the VESPER trials reported
According to ADA Meeting News, berobenatide is an investigational injectable GLP-1 receptor agonist being tested in phase 2b VESPER studies.
VESPER-2 studied weekly berobenatide in adults with obesity or overweight and type 2 diabetes over 28 weeks. The ADA report described dose-dependent decreases in A1C up to 2.2% and body-weight reductions up to 10.2%.
VESPER-3 studied monthly berobenatide in adults with obesity or overweight and hypertension and/or dyslipidemia. The primary endpoint was percent change in body weight at week 28. The ADA report described placebo-adjusted weight loss up to 12.3% with the 4.8 mg monthly dose, with the trial continuing for longer-term data.
ClinicalTrials.gov also lists a separate phase 3 study of once-monthly PF-08653944, the study medicine also known as berobenatide, in adults with overweight or obesity. That trial listing reinforces that this medicine is still being evaluated in research settings.
What this does not mean
- It does not mean berobenatide is available for routine diabetes or weight management care.
- It does not prove that berobenatide is better than approved GLP-1 or GIP/GLP-1 medicines.
- It does not tell us enough about long-term safety, rare side effects, durability of weight loss, or effects on heart, kidney, or liver outcomes.
- It should not be used to make individual treatment changes without a healthcare professional.
Practical takeaway
If you live with type 2 diabetes, obesity, or overweight, this news is worth following, but it is not something to act on today. If you are already using a GLP-1 medicine or considering one, discuss approved options, side effects, costs, and your personal risks with your diabetes or weight-management clinician.
People interested in research participation can ask their care team whether clinical trials are appropriate, but trial eligibility depends on medical history, current medicines, and study location.
Sources
- ADA Meeting News: Ultra-long-acting GLP-1 RA improves weight loss in individuals with and without type 2 diabetes
- ClinicalTrials.gov: A study of berobenatide (PF-08653944) in people with overweight or obesity
Editorial and verification notes
- OpenAI review checked the draft for medical accuracy, unsupported claims, dates, drug names, trial framing, regulatory caveats, and patient-safety tone.
- OpenRouter/Claude review checked the unpublished draft for accuracy, tone, and missing caveats before publication.
- OpenRouter/Perplexity verification checked the main claims against cited sources and required conservative wording because berobenatide remains investigational.